OncoCyte's EBITDA per Share for the
three
months ended in Sep. 2022 was $-0.07.
During the past 3 years, the average EBITDA Per Share Growth Rate was -26.00% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -7.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 9 years, the highest 3-Year average EBITDA Per Share Growth Rate of OncoCyte was 8.80% per year. The lowest was -26.00% per year. And the median was 3.25% per year.
Competitive Comparison
For the Biotechnology subindustry, OncoCyte's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoCyte 5-Year EBITDA Growth Rate Distribution
For the Biotechnology industry and Healthcare sector, OncoCyte's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where OncoCyte's 5-Year EBITDA Growth Rate falls in comparison to its industry or sector. The grey bar indicates the 5-Year EBITDA Growth Rate's extreme value range as defined by GuruFocus.
OncoCyte 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
OncoCyte 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of OncoCyte's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.03(7.86%) Volume: 164,716 12:56PM EST
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
OCX has been successfully added to your 
